Suppr超能文献

肠道菌群失调在心力衰竭的心血代谢危险因素中的新作用。

The Emerging Role of Gut Dysbiosis in Cardio-metabolic Risk Factors for Heart Failure.

机构信息

Human Neurotransmitters, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria, 3004, Australia.

Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, 99 Commercial Road, Melbourne, Victoria, 3004, Australia.

出版信息

Curr Hypertens Rep. 2020 May 8;22(5):38. doi: 10.1007/s11906-020-01046-0.

Abstract

PURPOSE OF REVIEW

To summarize the recent evidence that supports a role for the gut microbiota, microbiota-derived metabolites, and dysbiosis on cardiovascular risk factors, and to discuss the neuro-cardio-metabolic mechanisms that link gut microbiota and heart failure.

RECENT FINDINGS

There is growing evidence that the gut microbiota communicates with and impacts the cardiovascular system, contributing to the development of heart failure once it becomes out of balance (i.e. gut dysbiosis). The exact mechanisms of how the gut microbiota influences cardiovascular outcomes are not fully understood, but immune dysregulation and disturbance of neuro-enteroendocrine hormones seem to be involved. The disturbances in the gut microbiota influence the progression of several risk factors for heart failure, including atherosclerosis, obesity, diabetes, kidney disease and hypertension. In turn, these conditions also act to regulate the gut microbiota through the deterioration of the integrity of the intestinal barrier and the release of neurotransmitters and gastrointestinal hormones. In normal and healthy physiological conditions, these interactions are homeostatic and tightly controlled. However, a combination of environmental exposures (e.g. antibiotics use and Western diet) and the host's intrinsic conditions (e.g. genetics and fluid status) can result in the breakdown of intestinal homeostasis and further progression of cardiovascular risk factors, which lead to the development of heart failure. Manipulation of the gut microbiota may have the potential to improve cardiovascular outcomes by ameliorating immune system dysregulation, enteroendocrine disruptions, and neurohormonal activation in patients with cardiovascular risk factors for heart failure.

摘要

目的综述

总结近期有关肠道微生物群、微生物衍生代谢物和肠道菌群失调对心血管危险因素的作用的证据,并讨论将肠道微生物群与心力衰竭联系起来的神经心脏代谢机制。

最近的发现

越来越多的证据表明,肠道微生物群与心血管系统相互作用并对其产生影响,一旦失衡(即肠道菌群失调),就会导致心力衰竭的发生。肠道微生物群影响心血管结局的确切机制尚不完全清楚,但免疫失调和神经肠内分泌激素紊乱似乎与之相关。肠道微生物群的紊乱影响心力衰竭的几个危险因素的进展,包括动脉粥样硬化、肥胖、糖尿病、肾病和高血压。反过来,这些情况也通过破坏肠道屏障的完整性和释放神经递质和胃肠激素来调节肠道微生物群。在正常和健康的生理条件下,这些相互作用是稳态的,并且受到严格控制。然而,环境暴露(例如抗生素的使用和西方饮食)和宿主的内在条件(例如遗传和液体状态)的组合可能导致肠道内稳态的破坏,以及心血管危险因素的进一步进展,从而导致心力衰竭的发展。通过改善心力衰竭的心血管危险因素患者的免疫系统失调、肠内分泌紊乱和神经激素激活,肠道微生物群的操纵可能具有改善心血管结局的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验